Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 24, 2019 (7 years ago)

Losartan Potassium Tablets USP 25 mg 50 tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Losartan Potassium Tablets USP 25 mg 50 tablets (5x10) Unit Dose Rx Only NDC 50268-516-15 Manufactured for: AvKARE Inc. Pulaski, TN 38478

Affected NDC 50268-0516-15

Compare with the code on your package — it is the most precise check available.

Drug: Losartan Category: Blood Pressure Medication

Recalling firm
AVKARE Inc.
NDC code
50268-516-15
Origin
TN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1250-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Losartan recalls

See all

Other recalls by AVKARE Inc.

All 2019 recalls
Class II · Moderate risk

Amantadine HCl

Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.

Ongoing Dissolution failure AvKARE NDC 50268-069-15 D-0341-2026